KalVista Pharmaceuticals (KALV) Share-based Compensation (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Share-based Compensation data on file, last reported at $725000.0 in Q3 2025.

• For the quarter ending Q3 2025, Share-based Compensation fell 76.15% year-over-year to $725000.0; the trailing twelve-month figure through Jul 2025 stood at -$6.9 million (down 162.13% YoY), and the FY2025 full-year result was $725000.0, down 96.69% from the prior year.
• Share-based Compensation improved to $725000.0 in Q3 2025, from -$7.9 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $6.3 million in Q1 2023 to a low of -$7.9 million in Q2 2025.
• A 5-year average of $1.2 million and a median of $2.4 million in 2023 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation slumped 573.98% in 2022 and jumped 172.99% in 2023, its largest moves.
• Tracing KALV's Share-based Compensation over 5 years: stood at $2.9 million in 2021, then sank by 58.32% to $1.2 million in 2022, then soared by 169.04% to $3.2 million in 2023, then tumbled by 186.47% to -$2.8 million in 2024, then soared by 126.14% to $725000.0 in 2025.
• Business Quant data shows KALV's Share-based Compensation at $725000.0 in Q3 2025, -$7.9 million in Q2 2025, and -$2.8 million in Q4 2024.